GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Dr Lalchandani Labs Ltd (BOM:541299) » Definitions » Debt-to-EBITDA

Dr Lalchandani Labs (BOM:541299) Debt-to-EBITDA : 9.00 (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Dr Lalchandani Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dr Lalchandani Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹32.00 Mil. Dr Lalchandani Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹30.95 Mil. Dr Lalchandani Labs's annualized EBITDA for the quarter that ended in Sep. 2023 was ₹6.99 Mil. Dr Lalchandani Labs's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 9.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Dr Lalchandani Labs's Debt-to-EBITDA or its related term are showing as below:

BOM:541299' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -374.55   Med: 2   Max: 12.64
Current: 12.64

During the past 11 years, the highest Debt-to-EBITDA Ratio of Dr Lalchandani Labs was 12.64. The lowest was -374.55. And the median was 2.00.

BOM:541299's Debt-to-EBITDA is ranked worse than
93.14% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.79 vs BOM:541299: 12.64

Dr Lalchandani Labs Debt-to-EBITDA Historical Data

The historical data trend for Dr Lalchandani Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Lalchandani Labs Debt-to-EBITDA Chart

Dr Lalchandani Labs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 1.42 1.92 2.12 -374.55

Dr Lalchandani Labs Semi-Annual Data
Mar13 Mar14 Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 5.41 -21.41 21.59 9.00

Competitive Comparison of Dr Lalchandani Labs's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Dr Lalchandani Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr Lalchandani Labs's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Dr Lalchandani Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dr Lalchandani Labs's Debt-to-EBITDA falls into.



Dr Lalchandani Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dr Lalchandani Labs's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(30.874 + 33.174) / -0.171
=-374.55

Dr Lalchandani Labs's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(31.996 + 30.945) / 6.992
=9.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.


Dr Lalchandani Labs  (BOM:541299) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Dr Lalchandani Labs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Dr Lalchandani Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Dr Lalchandani Labs (BOM:541299) Business Description

Traded in Other Exchanges
N/A
Address
Greater Kailash, Part-1, M-20, Basement, South Delhi, New Delhi, IND, 110048
Dr Lalchandani Labs Ltd engages in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunology, virology, cytology, and other pathological and radiological investigations. It also offers Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA, and Genetic Testing. The company operates in two segments B2B sales and B2C sales, out of which the majority is from B2C sales. Revenue is generated from the sale of services.

Dr Lalchandani Labs (BOM:541299) Headlines

No Headlines